Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The data were presented in a poster session at the Society for Melanoma Research 2016
